Get started
Author

Katell Le Dû

Observed names: K. Le Du, K. Le DÛ, K. Le Dû, K. Le Du, K. le DÛ, Katell Genovefa Le Du, Katell LE DU, Katell LE DÛ, Katell Le Du, Katell Le Dû Sr, Le Du, Katell
Observed institutions: Centre National de la Recherche Scientifique, Inserm, University of Cologne, Centre Hospitalier Universitaire de Nantes, Centre Hospitalier Universitaire de Besançon, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, Assistance Publique – Hôpitaux de Paris, Centre Jean Bernard, Centre Hospitalier du Mans, Clinique Victor Hugo, Hôpital privé du Confluent, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University Hospital Cologne, Université de Nantes, Niigata University, Nantes Université
ORCID: 0000-0003-4371-2668
Observed ORCID: 0000-0003-4371-2668
OpenAlex ID: A5040156395
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
2019 · Kirsten Fischer, Othman Al-Sawaf, et al. · New England Journal of Medicine · 874
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
2018 · Steven Horwitz, Owen A O'Connor, et al. · The Lancet · 739
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
2017 · Steven Le Gouill, Catherine Thieblemont, et al. · New England Journal of Medicine · 416
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
2020 · Othman Al-Sawaf, Can Zhang, et al. · The Lancet Oncology · 339
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma
2017 · Thierry Lamy, Gandhi Damaj, et al. · Blood · 178
PDF
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
2018 · Judith Trotman, Sally F Barrington, et al. · The Lancet Oncology · 152
PDF
Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancer
2017 · Eric Voog, Loïc Campion, et al. · Supportive Care in Cancer · 72
Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi‐institutional retrospective study of 77 cases from the French Innovative Leukemia Organization ( FILO )
2017 · Eric Durot, Cécile Tomowiak, et al. · British Journal of Haematology · 55
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study
2021 · Vincent Camus, Cédric Rossi, et al. · Blood Advances · 52
PDF
Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium
2024 · Maria Alice Franzoi, Arlindo R. Ferreira, et al. · The Lancet Regional Health - Europe · 48
PDF
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
2022 · Marta Sobas, Jean-Jacques Kiladjian, et al. · Blood Advances · 47
Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group
2014 · Remy Gressin, Mary Callanan, et al. · Blood · 23
R-CHOP with or without Radiotherapy in Non-Bulky Limited-Stage Diffuse Large B Cell Lymphoma (DLBCL): Preliminary Results of the Prospective Randomized Phase III 02-03 Trial from the Lysa/Goelams Group
2014 · Thierry Lamy, Gandhi Damaj, et al. · Blood · 22
Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
2019 · Catherine Thieblemont, Susannah Howlett, et al. · British Journal of Haematology · 18
PDF
Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera
2023 · Yan Beauverd, Jean-Christophe Ianotto, et al. · Blood · 17
A New Option for Pain Prevention Using a Therapeutic Virtual Reality Solution for Bone Marrow Biopsy (REVEH Trial): Open-Label, Randomized, Multicenter, Phase 3 Study
2023 · Katell Le Du, Anne-Lise Septans, et al. · Journal of Medical Internet Research · 17
PDF
Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study
2014 · Valentin Goede, Anja Engelke, et al. · Blood · 15
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera
2025 · Yan Beauverd, Jean-Christophe Ianotto, et al. · Leukemia · 14
Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study
2018 · Benedicte Deau, Sandy Amorim, et al. · British Journal of Haematology · 13
PDF
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study
2024 · Caroline Dartigeas, Anne Quinquenel, et al. · Annals of Hematology · 9
PDF
Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Final Analysis of Phase II CONTRALTO Study
2018 · Pier Luigi Zinzani, Ian W. Flinn, et al. · Blood · 7
Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)
2019 · Herve Ghesquieres, Olivier Casasnovas, et al. · Blood · 5
Prospective study of a web-mediated management of febrile neutropenia related to chemotherapy (Bioconnect)
2018 · Fabrice Denis, Eric Voog, et al. · Supportive Care in Cancer · 4
Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study
2025 · Corentin Orvain, Suzanne Tavitian, et al. · HemaSphere · 3
PDF
Anaemia in Hospitalized Cancer Patients: A Retrospective Study of Two Cohorts before and after the Guideline Update
2024 · Katell Le Dû, Anne-Lise Septans, et al. · Oncology Research and Treatment · 3
Works count: 82
Citation count: 3,178
H-index: 16
I10-index: 19
Year
Topic
Type